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Abstract
Background: The Kuwaiti perspective on quality of life (QOL) in breast cancer is important
because it adds the contribution from a country where the disease affects women at a relatively
younger age and seems to be more aggressive. We used the EORTC QLQ – C30 and its breast-
specific module (BR-23) to highlight the health-related QOL of Kuwaiti women with breast cancer,
in comparison with the international data, and assessed the socio-demographic and clinical variables
that predict the five functional scales and global QOL (GQOL) scale of the QLQ – C30.
Methods: Participants were consecutive clinic attendees for chemotherapy, in stable condition, at
the Kuwait Cancer Control Center.
Results: The 348 participants were aged 20–81 years (mean 48.3, SD 10.3); 58.7% had stages III
and IV disease. Although the mean scores for QLQ – C30 (GQOL, 45.3; and five functional scales,
52.6%–61.2%) indicated that the patients had poor to average functioning, only 5.8% to 11.2% had
scores that met the </= 33% criterion for problematic functioning, while 12.0% to 40.0% met the
>66% criterion for more severe symptoms. Most (47.8%–70.1%) met the >66% criterion for "good
functioning" on the BR-23 functional scales. The mean scores of the QLQ – C30 indicated that,
despite institutional supports, Kuwaiti women had clinically significantly poorer global QOL and
functional scale scores, and more intense symptom experience, in comparison with the
international data (i.e., </= 10% difference between groups). For the BR-23, Kuwaiti women
seemed to have clinically significantly better functional scale scores, but more severe symptoms,
especially systemic side effects and breast symptoms. Younger women had poorer HRQOL scores.
In regression analysis, social functioning accounted for the highest proportion of variance for
GQOL.
Conclusion: The relatively high number that met the criterion for good functioning on the
functional scales is an evidence base to boost national health education about psychosocial
prognosis in cancer. In view of the poor performance on the symptom scales, clinicians treating
Kuwaiti women with breast cancer should prepare them for the acute toxicities of treatment and
address fatigue. The findings call for the institution of a psycho-oncology service to address psycho-
social issues.
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Background
In the field of medicine, one popular definition of the
construct of quality of life (QOL), based on the World
Health Organization's definition of health, is that it con-
cerns physical, psychological and social functioning,
incorporating positive aspects of wellbeing as well as neg-
ative aspects of disease [1] Health – related QOL
(HRQOL) is that aspect attributable to the disease and its
treatment, and generally consists of assessments of func-
tional health status (i.e., limitations on physical, psycho-
logical and social functioning imposed by the disease)
and global wellbeing [2].
Although there has been considerable research on the
QOL of women with breast cancer [3], the results may not
be significantly affecting clinical decision – making
because the clinical significance of findings is not speci-
fied [4,5]. More studies are therefore needed to make QOL
assessment feasible, understandable and scientifically via-
ble in oncology research and practice [5]. In particular,
HRQOL assessments in oncology facilitate doctor –
patient communication, they point to areas where
patients may experience serious problems, they can be
used as diagnostic tools for problem- oriented follow – up
care, and the data are strong predictors of survival [6,7].
These issues are highly relevant in Arab countries, such as
Kuwait, where there is paucity of studies on QOL in cancer
[8,9], and the development of modern oncology services
has led to improved survival rates, thereby making the dis-
ease to be a chronic condition. In addition, there are indi-
cations that different cultural groups may emphasize
different aspects of their QOL [10]. For example, analysis
of a large international database of the European Organi-
zation for Research and Treatment in Cancer Quality of
Life Questionnaire (EORTC QLQ – C30) indicated that,
compared with subjects from the UK, physical and social
functioning were less important in predicting the global
QOL of subjects from Islamic countries, while cognitive
functioning was more influential for South Asia and Latin
America [10]. This obviates the need to assess the local
perspectives on international QOL instruments, so that
the data can be used to guide the choice of interventions
and for cross-cultural comparisons to contribute to the
emerging QOL theory [11]. Accordingly, researchers have
sought to highlight the factors that predict HRQOL
among women with breast cancer. The common findings
are as follows: First, younger age and chemotherapy are
risk factors for diminished QOL [12-16]. Second, the asso-
ciation of stage of breast cancer with QOL is more contro-
versial, with some authors finding no significant
relationship [15,17], while others report significant
impact, in line with expectation of known groups validity
[3,9,18,19]. Also controversial is the impact on QOL, of
the type of breast surgery [12,14,15], and time since sur-
gery and chemotherapy [12,20]. Third, disease – free
women tend to have global QOL scores similar to the gen-
eral population [21].
In this study, we sought to present an Arab perspective on
the above issues, by using the EORTC QLQ – C30 [17]
and its breast cancer specific module (BR -23) [18] to
assess women attending the outpatient service of the
Kuwait Cancer Control Center (KCCC) for chemotherapy.
We chose the EORTC QLQ for the following reasons. First,
although it was articulated in Europe, it has been found to
be reliable and valid in diverse cultures, including, the
United Arab Emirates [9], Iran [19], Turkey [22], Japan
[23], India [13], China [24], Korea [25], and Nigeria [26].
Hence, there is an impressive body of international data
with which to compare our results. Second, an Arabic
translation of the questionnaire already exists, approved
by the authors of the instrument.
The Kuwaiti perspective is important because it adds the
contribution from a country where the pathobiological
features of the disease indicate that it affects women at a
relatively younger age and it seems to be more aggressive
than what is currently seen in Europe, North America,
Australia, and parts of Asia [27]. In addition, the highly
developed cancer service at the KCCC is easily accessible
to all in this materially affluent city – state, and is pro-
vided free – of – charge to all Kuwaiti nationals. Since met
needs for care have been known to be associated with
QOL [28,29], one wonders whether these favorable
social/institutional care factors could contribute to make
the HRQOL of Kuwait women to be comparable to the
international data, despite the unfavorable factors (e.g.,
pathobiological features mentioned above, and use of
chemotherapy). In Kuwait, breast cancer is the most com-
mon malignancy among women, accounting for 30.3% of
all cancer types, and death occurs in approximately 43%
of patients [27].
Objectives
The objectives of the study were as follows: First, to high-
light the HRQOL scale scores for Kuwaiti women in stable
clinical condition with breast cancer, in comparison with
the international data. Second, to examine the association
of HRQOL with socio-demographic characteristics, stage
of disease, type of treatment received in the past (i.e., sur-
gery and radiotherapy), and duration since last treatment
(for chemotherapy, surgery and radiotherapy). Third, to
assess the variables that predict the global health status/
QOL scale (GQOL) and the five functional scales of the
QLQ – C30 (i.e., physical, role, emotional, cognitive, and
social functioning), in comparison with the international
data. In particular, we examined the relationship between
GQOL, the five functional scales and the symptom scales/
items [10].BMC Cancer 2009, 9:222 http://www.biomedcentral.com/1471-2407/9/222
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Based on the literature, we hypothesized that despite
unfavorable biological/treatment factors (i.e., their rela-
tively younger age, more aggressive tumor and the fact
that most were on chemotherapy at the time of assess-
ment) [12-16], Kuwaiti women would have comparable
HRQOL scores with the international data because of
favorable social/care factors [28,29]. Second, there is sig-
nificant association between HRQOL scale scores and
other demographic variables, stage of disease, time since
last treatment, and previous surgery and radiotherapy.
Third, as indicated by data from other Islamic countries
[10], physical and social functioning would be less impor-
tant in predicting the GQOL. On the other hand, since the
occurrence of physical symptoms can cause a change in
QOL [30] the symptom scales will be prominent predic-
tors of GQOL.
Methods
Subjects and setting of the study
The subjects were consecutive attendees at the outpatient
clinic of the medical oncology department of the KCCC
who fulfilled the study's inclusion criteria. They were
attending follow-up clinic appointment for chemother-
apy. No restrictions were made with regard to age and type
of chemotherapy [18]. In order to make our findings com-
parable with those of others, participants were in stable
clinical condition (i.e., were not in acute pain, could move
about unassisted, did not require hospitalization), had
clear consciousness, could easily follow the interview
process, and could independently give consent to partici-
pate in the study [31]. In this culture, female patients are,
as a rule, accompanied to hospital by family members
who live with them [32]. Consent was also obtained from
the family members; but the patients were interviewed
privately in one of the clinic rooms designated for the
study. Patients involved in this study were Kuwaiti nation-
als.
The KCCC is the national center for treatment of cancer,
and houses the National Cancer Registry, the Kuwait
National Cancer Control Program (in collaboration with
the WHO), the Radiation Oncology and Nuclear Medi-
cine Departments, as well as the Medical, Pediatric, and
Surgical Oncology Departments, and diagnostic facilities.
All cancer cases in the country are referred there. It is an
ultra-modern facility, with adequate facilities for diagno-
sis and treatment of cancer. It has a large complement of
specialists in the various fields of oncology. There are
daily outpatient clinics and 190 inpatient beds. All serv-
ices are rendered free – of – charge to Kuwaitis, while oth-
ers pay nominal fees.
Since this study was not a drug trial, we included patients
with all types of treatment, as determined by their doctors.
Hence, patients received a wide variety of chemotherapy.
The EORTC QLQ – C30 and BR – 23
The EORTC QLQ – C30 is a 30 – item generic HRQOL
instrument designed to assess cancer patients' physical,
psychological and social functioning [17,31]. It is com-
posed of nine multi-item scales: 5 functional scales (listed
above), a global QOL scale (GQOL), and three symptom
scales (fatigue, pain, nausea & vomiting). In addition,
there are five single item symptom scales (dyspnea, sleep
disturbance, appetite loss, constipation, & diarrhea); and
a final item evaluates the perceived financial impact of the
disease. In the version used for this study (version 3), the
first 28 items are rated on a response scale of "not at all
(1), to "very much" (4). The time frame is the present
moment. For items 29 (on overall general health) and 30
(on overall QOL), the response options range from "very
poor" (1) to "excellent" (7), and the time frame is "during
the past week".
The 23 – item breast cancer -specific module, the QLQ -BR
-23 [18], consists of two multi-item functional scales
(body image and sexual functioning), three symptom
scales (systemic side effects, breast symptoms, & arm
symptoms), and three single item scales on sexual enjoy-
ment, future perspectives, and upset by hair loss. The
response options are "not at all" (1), to "very much" (4),
and the time frame is "during the past week", except for
the sexual items ("during the past four weeks"). The scor-
ing algorithm recommended by the EORTC [33], was
used to transform the responses to values on a scale of 0 –
100%. For the functional scales and GQOL, a higher score
corresponds to better functioning and QOL. For symptom
scales, a higher score corresponds to more frequent and/
or more intense symptoms. A problematic group is
defined as one with a GQOL or functional scale score of
33 or less, and a symptom scale score of 66 or more on the
QLQ – C30 and QLQ – BR-23 [20,28].
We assessed the internal consistency of the questionnaires
by estimating the Cronbach's alpha values of the multi-
item scales, based on the recommendation of > 0.70. The
alpha coefficients were highly significant: for the first 28
items of the QLQ – C30, it was 0.94 (split half reliability
= 0.84). For the 23 items of the BR-23, the alpha coeffi-
cient was 0.92 (split -half reliability = 0.81).
Data collection procedure
At the preliminary stage of the study, the EORTC Quality
of Life Unit in Belgium, kindly sent us the questionnaires
(English & Arabic translations) and the scoring manual.
The study was carried out in compliance with the Helsinki
Declaration. Hence, ethical approval for the work was
obtained from the institutional review panel of the KCCC.
In addition, patients and their family caregivers gave ver-
bal informed consent to participate in the study. TheyBMC Cancer 2009, 9:222 http://www.biomedcentral.com/1471-2407/9/222
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were duly informed that there would be no negative con-
sequences for declining to participate. As is well known in
our culture for such non-invasive studies [32], all families
approached freely consented to participate in the study,
especially as the approach was made by clinic staff in
charge of the cases.
All assessments were based on private interviews by a
trained female Arab research assistant, who has had previ-
ous experience in administering QOL questionnaires. The
research assistant read out the questions to the partici-
pants and rated their responses. The criteria for staging
disease by the doctors were those of the American Joint
Committee on Cancer [34].
Data analysis
Data were analyzed by the Statistical Package for Social
Sciences, version 15 for windows (SPSS Inc., Chicago, Illi-
nois). The scale scores of the QLQ – C30 and BR-23 were
computed as recommended [33]. In order to test the first
hypothesis, we used scale scores adjusted for age, occupa-
tion, marital status and stage of cancer, to compare our
data with similar reports from the neighboring United
Arab Emirates (UAE), various European countries, and
Asia. These reports were located by a limited Medline
search for recent English language papers that concerned
patients in stable condition from various regions of the
world, using the key words: EORTC QLQ – C30; breast
cancer. Comparisons were done by effect size calculations
and by adopting the operational definition of a clinically
meaningful (significant) difference of 10% between
groups [5,35]. Where effect size calculations were done for
HRQOL scales, we defined a clinically significant differ-
ence as ≥ 0.5 [36]. For the functional scales and the
GQOL, we defined subjects with problematic functioning
as those who scored ≤ 33%, while subjects in good condi-
tion scored >66%. For symptom scales, subjects scoring ≤
33% were judged as having less severe symptoms, while
those scoring > 66% had more intense symptoms [20].
We have used the ≤ 33% cut-off scale score to categorize
the patients because that score was suggested from an
empirical general population study [37], rather than the-
oretical speculation. For the second hypothesis, we ana-
lyzed the association of scale scores with socio-
demographic and clinical variables, by Pearson's correla-
tions, t-tests and one-way ANOVA. The strength of these
relationships was tested in multivariate analysis by analy-
sis of covariance (ANCOVA). For the third hypothesis, we
used multiple (stepwise) regression analyses to assess the
predictors of the functional scales and GQOL scale of the
QLQ – C30. With each of the functional scales as depend-
ent variable, the independent (predictor) variables were
entered in blocks, starting from the background socio-
demographic and clinical variables, followed by the other
functional scales, then the symptom scales, and finally,
the single item scales of the QLQ – C30. In the case of the
GQOL, the scales of the BR-23 were also entered as inde-
pendent variables. Missing data were handled by deleting
cases, analysis- by- analysis. Where there was multiple
testing, we used a Bonferroni correction of P < 0.01. Oth-
erwise, the level of significance was set at P < 0.05, and all
tests were two-tailed.
Results
Socio-demographic and clinical characteristics (Table 1)
Over a period of one year (2007/2008), 348 women ful-
filled the study's inclusion criteria and freely agreed to
participate. They were aged 20 – 81 years (mean, 48.3, SD
10.3; median & mode = 46). Only six subjects (1.7% of
345) were aged < 30 years, while 82 (23.8%) were aged >
55 years. This age pattern is much similar to breast cancer
Table 1: Socio – demographic and clinical characteristics of 
breast cancer patients
Variables No. of subjects (%)
Age groups (yrs): N = 345
20 – 39 60 (17.4)
40 – 59 232 (67.2)
60 – 81 53 (15.4)
Mean (SD): 48.3 (10.3); Median, & Mode = 46.0
Marital status: N = 347
Married 312 (89.9)
Single 11 (3.2)
Divorced/widow 24 (6.9)
Occupational status: N = 343
Housewife/retired 75 (21.9)
Low skill work (e.g., clerk) 45 (13.1)
Medium skill (e.g., school teacher) 191 (55.7)
High skill work (e.g., doctor, lawyer, engineer) 32 (9.3)
Stage of cancer (N = 344)
I 24 (7.0)
II 118 (34.3)
III 124 (36.0)
IV 78 (22.7)
Type of treatment received
Chemotherapy 342 (98.3)
Radiotherapy 73 (21.0)
Surgery 204 (58.6)
Duration since last chemotherapy (N = 341)
Past month 315(92.4)
1 month to 3 months 13 (3.8)
> 3 months 13 (3.8)
Duration since last radiotherapy: N = 69
Past month 48(70.7)
1 – 6 months 4 (5.7)
> 6 months 17 (24.6)
Duration since last surgery: N = 202
Past month 49(24.3)
1 – 3 months 78(38.6)
> 3 months 75 (37.1)
Those with stage IV disease were older (51.0) than those with other 
stages. This reached significance in comparison with stage III patients 
(46.9), (F = 2.7, df = 3/341, P < 0.05).BMC Cancer 2009, 9:222 http://www.biomedcentral.com/1471-2407/9/222
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clinic samples in previous reports from Kuwait [27,38].
The participants were predominantly married (89.9%),
and in full employment (78.1%). Majority (58.7) were
being treated for advanced disease (i.e., stages III & IV).
Apart from chemotherapy, majority (58.6%) had had sur-
gery, while 21% had received radiotherapy. Most (92.4%)
had received a course of chemotherapy in the past month.
Profile of HRQOL scale scores (Tables 2 and 3)
Of the QLQ – C30 scales, the patients seemed to perform
poorly to averagely on both the symptom scales and the
functional health status scales. Hence, of the functional
scales, the mean score for the global QOL scale (GQOL)
was less than 50%, while the range of mean scores for the
five scales was 52.6% to 61.2%, indicating predominantly
low level of general wellbeing with average level of func-
tional health status. Judging by the cut-off score of 66%,
the best domains of functioning were "cognitive" and
"social", where just over one-half of participants had good
level of functioning. The domains with poorest function-
ing were general wellbeing and physical functioning,
where only 10.9% – 25.2% had good level of functioning.
It is noteworthy that only 6.5% to 11.2% had scores that
met operational criterion for problematic functioning in
the functional domains.
They performed much worse on the symptom scales,
because 13.6% to 40.0% met the operational criterion for
significantly high levels of symptoms. The commonest
problem areas (i.e., over one- quarter had "problematic"
scores) were, pain, dyspnoea, sleep disturbance and poor
appetite. However, 18.3% to 54.8% met the operational
criterion for "good" functioning for the symptom scales.
The patients performed best on the functional scales of
the breast specific scales (BR-23) because most (47.8 –
70.1%) met the operational criterion for "good" function-
ing. In particular, about two-thirds had good sexual func-
tioning and were optimistic about their future health,
while almost one-half expressed little or no problems
with their body image.
Of the BR-23 symptom scales, the commonest area with
significantly intense level of symptom experience was hair
loss. However, 17.2% – 42.3% seemed to be relatively free
Table 2: QLQ – C30 & BR -23 unadjusted scale scores, percentage of subjects with problems & in good conditiona.
Variables N No. of
items
Mean (SD) 95% C.I. % scoring < 33.3%c % scoring ≥ 66.7%c
C-30 Functional scalesb
Global QOL/general health 340 2 45.3(15.3) 43.7 – 46.9 6.2 10.9
Physical functioning 330 5 52.6(18.8) 50.6 – 54.6 11.2 25.2
Role functioning 340 2 55.1(21.4) 52.7 – 57.5 7.6 39.1
Emotional 323 2 60.3(22.5) 57.7 – 62.9 8.4 45.2
Cognitive 342 4 59.9(23.9) 57.3 – 62.5 5.8 51.2
Social 339 2 61.2(22.7) 58.8 – 63.6 6.5 52.8
C – 30 symptoms/scalesc
Fatigue 331 3 38.9(21.3) 36.5 – 41.3 29.0 13.6
Nausea & vomiting 334 2 30.2(24.5) 27.6 – 32.8 48.5 12.0
Pain 334 2 43.8(21.7) 41.4 – 46.2 20.1 27.5
Dyspnoea 335 1 42.4(27.8) 39.4 – 45.4 18.8 40.0
Sleep disturbance 338 1 42.7(28.2) 39.7 – 45.7 18.3 39.3
Appetite loss 339 1 37.5(28.0) 34.5 – 40.5 25.1 32.7
Constipation 345 1 27.8(28.2) 24.8 – 30.8 42.0 22.0
Diarrhea 343 1 22.1(27.5) 19.1 – 25.1 54.8 19.2
Financial impact 344 1 31.2(25.2) 28.4 – 34.0 29.1 19.8
QOL – BR23: Functional scalesb
Body image 299 4 61.8(23.3) 59.0 – 64.6 7.0 47.8
Sexual functioning 303 2 69.9(23.6) 67.1 – 72.7 1.3 68.0
Sexual enjoyment 221 1 61.5(23.0) 58.3 – 64.7 2.3 70.1
Future perspective 334 1 59.5(31.9) 56.1 – 62.9 11.7 64.7
BR23: Symptom scalesc
Systemic side effects 300 7 40.1(17.5) 38.1 – 42.1 29.3 6.7
Breast symptoms 293 4 35.6(25.4) 32.6 – 38.6 42.3 14.3
Arm symptoms 318 3 38.2(23.4) 35.6 – 40.8 33.0 13.8
Upset by hair loss 331 1 44.8(29.6) 41.6 – 48.0 17.2 40.8
aFor functional scales, subjects scoring < 33.3% have problems; those scoring ≥ 66.7% have good functioning. For symptom scales/symptoms, 
subjects scoring < 33.3% have good functioning; those scoring = 66.7% have problems
b For functional scales, higher scores indicate better functioning
c For symptom scales, higher scores indicate worse functioningBMC Cancer 2009, 9:222 http://www.biomedcentral.com/1471-2407/9/222
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from intense levels of symptoms for the breast -specific
symptom scales.
Factors associated with HRQOL scale scores
Using Pearson's correlation analysis, the correlation of age
with scale scores was low (i.e., < 0.2). The correlations
were significant and positive for the following functional
scales: emotional functioning, cognitive functioning,
social functioning, sexual enjoyment, body image (r
ranged from 0.12 to 0.18, P < 0.02), and sexual function-
ing (r = 0.21, P < 0.0001). The correlations were signifi-
cant and negative for the following symptom scales:
systemic side effects, breast symptoms, arm symptoms,
upset by hair loss (r ranged from -0.14 to -0.19, P < 0.01).
In other words, for the functional and symptom scales,
older patients tended to have better functioning and less
intense symptoms than the younger patients.
Using Pearson's correlation analysis for the symptom
scales of the QLQ – C30, the correlation with GQOL was
highest for fatigue (r = 0.21, P < 0.0001). In one-way
ANOVA, marital and occupational status were not signifi-
cantly associated with scale scores (P > 0.05). Subjects
with advanced disease tended to have worse functioning.
This reached significance for the following: role function-
ing (stage IV < stage II, F = 3.8, df = 3/335, P < 0.01),
diarrhea (stage IV < stages I & II, F = 3.5, df = 3/338, P =
0.02), and future perspectives (stage III < stages I & II, F =
3.5, df = 3/329, P = 0.02). Those who had surgery had sig-
nificantly less complaints about diarrhea (t = 2.8, df =
268, P = 0.005), but more breast symptoms (t = 2.1, df =
227, P < 0.04).
Those who received radiotherapy had significantly more
problems with fatigue (t = 2.2, df = 185, P = 0.03), breast
symptoms (t = 2.1, df = 159, P = 0.04), arm symptoms (t
= 2.3, df = 175, P = 0.02), and future perspectives (t = 2.3,
df = 187, P = 0.02).
There was no significant consistent trend in the associa-
tion between scale scores and duration of last treatment
for surgery and radiotherapy.
In ANCOVA, with age, stage of cancer, marital status,
occupation, and duration since last chemotherapy as cov-
ariates, age was a significant covariate for sexual function-
ing (F = 5.7, P < 0.02); marital status was a significant
covariate for sexual enjoyment (F = 5.5, P < 0.02); and
time since chemotherapy was a significant covariate for
future perspectives (F = 6.1, P < 0.02) and body image (F
= 4.9, P < 0.03).
Predictors of global QOL and functional scale scores 
(Table 4)
In stepwise regression analyses, with the GQOL and func-
tional scales, each, as dependent variables, the following
trends emerged: First, the socio-demographic variables
that entered the regression equations (i.e., age, occupa-
tional status and marital status) played rather marginal
roles (i.e., variance 2.2 – 5.2%) in predicting GQOL, phys-
ical functioning and social functioning, respectively. Sec-
ond, the clinical variables did not enter the equations.
Third, the functional scales were more important (i.e.,
accounted for the highest proportion of variance) than the
symptom scales. Fourth, the variables that accounted for
the highest proportion of variance for each scale were as
follows: (i) for global QOL, social functioning; (ii) for
physical functioning, role functioning; (iii) for role func-
tioning, physical functioning; (iv) for emotional function-
ing, cognitive functioning; (v) for cognitive functioning,
emotional functioning; and (vi) for social functioning,
emotional functioning. Fifth, financial difficulty was a
highly significant predictor of global QOL (P < 0.007) and
social functioning (P < 0.001).
Discussion
Profile of EORTC QLQ – C30 and BR-23 scores
We assessed 348 predominantly middle aged Arab
women who were mostly receiving chemotherapy. The
mean scores for QLQ – C30 and BR-23 indicated that the
Table 3: QLQ – C30 & BR – 23 adjusted scale scores*
Variables N Mean (SE) 95% C.I.
QLQ C-30 functional scales
Global QOL/general health 331 45.0(0.8) 43.4 – 46.7
Physical functioning 316 52.7(1.1) 50.6 – 54.8
Role functioning 331 55.1(1.2) 52.7 – 57.4
Emotional 314 60.2(1.8) 57.7 – 62.7
Cognitive 333 59.4(1.3) 57.3 – 62.5
Social 330 61.3(1.3) 58.9 – 63.8
QLQ C – 30 symptoms scales
Fatigue 322 38.9(1.2) 36.5 – 41.2
Nausea & vomiting 326 30.2(1.3) 27.5 – 32.8
Pain 325 43.8(1.2) 41.4 – 46.2
Dyspnoea 327 42.1(1.5) 39.1 – 45.1
Sleep disturbance 329 42.7(1.6) 39.5 – 45.6
Appetite loss 330 37.4(1.5) 34.4 – 40.4
Constipation 336 27.8(1.5) 24.8 – 30.8
Diarrhea 334 21.9(1.5) 19.0 – 24.9
Financial impact 335 31.2(1.4) 28.5 – 33.9
QOL – BR23: functional scales
Body image 290 61.8(1.4) 59.2 – 64.5
Sexual functioning 295 70.2(1.3) 67.6 – 72.9
Sexual enjoyment 215 61.8(1.6) 58.7 – 64.9
Future perspective 325 59.7(1.8) 56.3 – 63.1
QLQ – BR23: Symptom scales
Systemic side effects 292 40.2(1.0) 38.2 – 42.2
Breast symptoms 284 35.3(1.5) 32.4 – 38.3
Arm symptoms 309 38.2(1.3) 35.6 – 40.8
Upset by hair loss 323 44.4(1.6) 41.2 – 47.6
* Scores adjusted for age, stage of cancer, marital status, and 
occupation
For functional scales, higher scores indicate better functioning
For symptom scales, higher scores indicate worse functioningBMC Cancer 2009, 9:222 http://www.biomedcentral.com/1471-2407/9/222
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patients had poor to average functioning and intense
symptom experience. We shall now examine the signifi-
cance of these findings in the context of the international
data.
The literature on EORTC QLQ has emphasized that com-
parison of data should go beyond the usual presentation
of mean scores and significant differences [4,35,39,40].
Towards this end, Table 2 shows that, although the mean
scores for QLQ – C30 indicated that the patients had poor
to average scale scores, only 5.8% to 11.2% had scores
that met the ≤ 33% criterion for problematic functioning,
while 12.0% to 40.0% met the >66% criterion for more
severe symptoms. In other words, despite the reality and
popular perception of cancer as a killer disease, many
patients undergoing effective modern treatment can
expect to have tolerable levels of physical, psychological
and social functioning and subjective wellbeing [41-43].
This was particularly the case for the functional scales of
the BR-23, where majority of subjects had scores indicat-
ing good functioning. It is interesting that, despite their
condition, about one-third were hopeful about the future.
These findings constitute an evidence base for the coun-
try's cancer control program, to boost national health
education about prognosis in cancer [8].
With regard to the pattern of functional scale scores of the
QLQ – C30, the pattern of responses of our patients was
similar to the international data for moderately extensive/
severe disease, because the lowest scores were noted for
physical functioning and role functioning, while the high-
est scores were for cognitive and social functioning [44].
This is in line with the reality of a severely debilitating
physical illness, where the much available family social
support and institutional support can help to boost psy-
chosocial wellbeing [28].
Factors associated with HRQOL
Of the factors investigated, the noteworthy associations
with HRQOL in univariate analyses were age, stage of can-
cer, receipt of radiotherapy and fatigue. Although the cor-
relations of age with scale scores were rather low, the
Table 4: Predictors of functional health status and global quality of life
Dependent variable Predictors or independent
variables
% Variance Total
vari-
ance
Standardized
Beta
T value P level
Global QOL & General health Social functioning 11.6 29.7 -0.31 3.2 0.002
Sexual enjoyment 4.5 -0.26 3.1 0.003
Pain 4.4 -0.33 3.5 0.001
Financial difficulty 4.1 0.24 2.8 0.007
Age 5.2 -0.14 1.9 0.07
Physical functioning Occupational status 2.2 53.3 0.9 1.7 0.09
Role functioning 45.7 0.51 8.0 0.0001
Cognitive functioning 5.4 0.29 4.6 0.0001
Role functioning Physical functioning 47.2 67.7 0.31 5.2 0.0001
Cognitive function 5.5 0.01 0.14 0.89
Social function 1.8 0.07 1.2 0.22
Pain 7.2 -0.30 4.5 0.0001
Fatigue 1.8 -0.11 1.7 0.09
Dyspnoea 1.9 -0.19 3.3 0.001
Appetite loss 1.2 -0.15 2.9 0.004
Constipation 1.0 0.13 2.3 0.02
Emotional functioning Cognitive functioning 59.6 67.7 0.48 7.4 0.0001
Social function 3.3 0.18 3.4 0.001
Pain 1.8 -0.11 1.8 0.08
Nausea & vomiting 0.08 -0.0.5 0.8 0.42
Constipation 0.02 -0.19 3.6 0.0001
Cognitive functioning Emotional functioning 59.6 69.4 0.47 7.6 0.0001
Physical function 6.7 0.21 3.9 0.0001
Social function 1.2 0.12 2.2 0.03
Nausea & vomiting 1.2 -0.11 2.1 0.04
Pain 0.7 -0.13 2.1 0.04
Social functioning Marital status 2.2 47.3 -0.11 2.0 0.05
Emotional functioning 35.1 3.5 5.1 0.0001
Role function 4.4 0.11 1.5 0.14
Fatigue 2.3 -0.19 2.8 0.006
Finance difficulty 3.4 -0.21 3.4 0.001BMC Cancer 2009, 9:222 http://www.biomedcentral.com/1471-2407/9/222
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results are in line with the international data in showing
that younger women with cancer tend to have poorer
functioning and more intense symptoms, especially if
they are on chemotherapy [12-16]. It has been suggested
that younger patients are more likely to suffer adverse
effects because of induction of early menopause and pos-
sible infertility [12]. While the finding of association of
disease stage with HRQOL scale scores indicates that the
questionnaire has known groups validity, the significant
associations were only for three scales (role functioning,
diarrhea and future perspective). In the studies that found
no significant association between QOL and cancer stage
at diagnosis, it has been suggested that the diagnosis of
breast cancer is so stressful that it may result in a pattern
of psychological morbidity for women in early stages that
is similar to that experienced by women with more
advanced disease [15]. Coupled with the indication that
future perspectives and body image perceptions were bet-
ter for those who had last treatment over a month ago,
[12,45], the above findings should be an evidence base for
the contents of a cancer counseling clinic for our patients.
Predictors of HRQOL
The highlight of our regression analyses is that, contrary to
the third hypothesis[30], the functional scale scores were
more important in predicting functional scales, than the
scores of the symptom scales, while social functioning
accounted for the highest proportion of variance in
GQOL. This is in line with a Canadian report, which indi-
cated that social functioning was strongly correlated with
global QOL, while physical and role functioning were
highly correlated [46]. This result has been explained
from the perspective of the phenomenon of response -
shift [45], which occurs if the patient's perception of the
severity of the symptoms changes over time. It is suggested
that many patients gradually adapt to the situation fol-
lowing diagnosis and treatment, becoming better at cop-
ing with symptoms, such that the patients no longer
perceive the burden of the symptoms to be as great as the
first time [45]. Hence, for such patients, the physical,
emotional and social limitations of the illness tend to
become more important determinants of QOL rather than
the physical symptoms. However, in a German study that
assessed the role of the symptom scales in predicting
HRQOL, it was found that fatigue was the most important
predictor of QOL [47]. While pain was the only symptom
scale that entered our regression model for GQOL, we
note that, in univariate analysis, fatigue had the highest
correlation with GQOL, of the symptom scales of the
QLQ-C30; and fatigue was a significant predictor for
social functioning (2.3% variance, P < 0.006). Hence, cli-
nicians should pay particular attention to how to alleviate
fatigue, in addition to the usual emphasis on pain [47].
The predictive power of financial difficulty shows that,
despite institutional supports, cancer is associated with
significant family financial burden. It appears that,
although treatment was provided free -of -charge, families
still made significant out -of -pocket expenses.
Comparison with the international data (additional file 1)
The relative youth of our subjects, in comparison with the
international data, is noteworthy. The life expectancy at
birth for Kuwaiti women is 78.95 years (2009 estimate:
https://www.cia.gov/library/publications/the-world-
factbook/geos/KU.html). The following pattern emerged
in comparing our scale scores with those of the interna-
tional EORTC QLQ data (additional file 1)[48,49], as well
as previous Kuwaiti QOL data from a general population
study [50] and women with multiple sclerosis [32], using
the global QOL scale of the 26-item WHOQOL-Bref. First,
for the functional scales of the QLQ – C30, the Kuwaiti
global QOL score was less than those of other countries by
at least 10%. In particular, the GQOL score from the
neighboring UAE was 20% higher, while that for three
Islamic countries was 14% higher. The pattern was the
same for physical and role functioning, except role func-
tioning data from China [24]. For emotional functioning,
Kuwaiti scores were at least 10% less than the data from
Korea, Sweden, and other Western nations. The tendency
for the emotional functioning data from the UAE and
three Islamic countries to be higher than that from
Kuwait, did not reach significance (Effect size: 0.22, 95%
C.I. = -0.02 – 0.46). For cognitive and social functioning,
Kuwaiti scores were at least 10% less than the data from
the UAE, the three Islamic countries and the Western
nations.
Second, for the symptom scales of the QLQ – C30, the
Kuwaiti data indicated more intense symptoms for dysp-
noea, appetite and diarrhea and more financial difficulty
(i.e., at least 10% difference).
Third, for the functional scales of the BR – 23, our data
was at the middle of the range of the international data for
body image, being much similar to the data from Iran and
China, indicating better functioning than the Korean data
(over 20% difference), but worse functioning than most
data from the Western world. For sexual functioning, the
Kuwaiti data was at the top of the range of the interna-
tional data, being similar to the Iranian and UAE data, but
indicating better functioning for most data from the West-
ern world. Fourth, of the symptom scales of the BR-23, the
mean scores indicated that Kuwaiti women had more
intense symptoms than women from all the comparison
countries for systemic side effects, breast symptoms and
arm symptoms. Regarding systemic side effects, Kuwaiti
women had at least 10% difference with women from the
Western world, Korea, and Iran, but similar scores with
women from the UAE (Effect size, 95% C.I: 0.09, -0.15 -
0.33). The pattern was the same for breast symptoms,BMC Cancer 2009, 9:222 http://www.biomedcentral.com/1471-2407/9/222
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except that the Kuwaiti women had clinically significantly
more intense symptoms than the women from the UAE.
Fifth, using the 0–100% scale of the WHOQOL-
Bref[32,50], Kuwaiti women in the general population,
women in the general population who rated themselves
as being sick, and women attending clinic for multiple
sclerosis, all had significantly higher global QOL scores
than the women with breast cancer (Effect size, 95% C.I:
1.22, 1.10 – 1.35; and 0.83, 0.60 – 1.05, respectively.
Comparison Kuwaiti data were adjusted for socio-demo-
graphic variables).
In summary, the profile of scale mean scores for QLQ –
C30 indicated that Kuwaiti women had clinically signifi-
cantly poorer global QOL and functional scale scores, and
more intense symptom experience for most scales, in com-
parison with the international data, including data from
neighboring Islamic countries. For the breast specific scale
(BR-23), Kuwaiti women seemed to have clinically signifi-
cantly better sexual functioning, but more severe treatment
side effect symptom experience, especially systemic side
effects and breast symptoms. The poor global QOL score of
Kuwaiti women with cancer was confirmed by the fact that
they had significantly lower scores than their compatriots
in the general population and those with multiple sclerosis.
It appears, therefore, that the experience of clinically more
severe symptoms among Kuwaiti women, as a group, was a
significant contributor to their low global QOL and com-
paratively poorer physical, emotional and social function-
ing [30]. In view of this, clinicians treating Kuwaiti women
for cancer should take particular interest in preparing the
patients for the acute toxicities of breast cancer treatment
[12]. Other factors that could have contributed to their
comparatively poor HRQOL are, their relative youth, the
fact that they were on chemotherapy [12-16], and the
aggressive histopathologic picture of breast cancer in
Kuwait [27]. In other words, the biological and treatment
side effect factors seemed to be more important than family
and institutional supports in the cross-sectional HRQOL
outcome of our patients. A longitudinal study is needed to
confirm this trend. However, we note that the laudable
institutional supports did not include any program on psy-
cho-oncology. Our general experience is that women with
breast cancer do not receive any formal psycho-education
on the nature of the illness, the implications of treatment
and how to cope with cancer. Our findings, therefore, call
for a formal program of psycho-oncology at the KCCC, to
counsel patients on the nature of the disease and treatment
side effects, address their psychosocial concerns and
explore methods of coping [51].
Limitations and strengths of the study
Our findings cannot be generalized to the general popula-
tion of women with breast cancer because the study was
cross-sectional, the participants were a selected clinic pop-
ulation, and there is no general population reference data
for the EORTC QLQ – C30 in Kuwait [52]. In addition, we
did not sort the patients into categories of disease progres-
sion and disease free survivors [28], and the fact that the
responses were based on interview could have introduced
a bias for patients who may have wished to respond pri-
vately. However, we have used an internationally well val-
idated questionnaire to describe the HRQOL of a fairly
large number of breast cancer survivors, and we have pre-
sented our results in such a way as to make them compa-
rable with data from other countries. Also, there is
published data on general population norms for a popu-
lar QOL instrument (WHOQOL -BREF) that was pre-
sented using the 0 – 100% scale (or the percentage scale
maximum method – % SM) [50]. The value of the %SM
measure is that it can be used for making comparison with
the scale scores of other questionnaires [53].
Of the Arabic samples reported in the literature [9,10],
ours is the largest. Furthermore, we categorized scale
scores into those with/without significant problems
[20,28,37], and applied the principle of clinically signifi-
cant difference in scale scores between groups [35] to
compare our results with the international data. Hence,
we met the need to provide clinically-based benchmarks
in interpreting QOL data, so as to make them meaningful
to clinicians[4,5,44]. Finally, it appears that our patients
had similar demographic characteristics with those of
breast cancer clinic populations in Kuwait [27,38].
Conclusion
The relatively high number that met the criterion for good
functioning on the physical, role, emotional, cognitive,
social, and sexual functioning scales is an evidence base to
boost national health education about psychosocial prog-
nosis in cancer. Their sense of optimism in the face of such
a devastating disease is particularly noteworthy. However,
in view of their poor performance on the symptom scales,
clinicians treating Kuwaiti women with breast cancer
should take particular interest in preparing the patients
for the acute toxicities of treatment, as well as addressing
fatigue and pain [12,47]. The findings call for the institu-
tion of a psycho-oncology service at the KCCC, to address
psycho-social outcome.
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